Skip to main navigation
  • Careers
  • Partnerships & Business Development
  • Contact Us
Link to  Esperion Therapeutics, Inc. Homepage
  • Company
    • About Us
    • Leadership Team
    • Board of Directors
    • Ethics and Compliance
    • Corporate Governance & Committee Composition
  • Products
  • Science
    • Unmet Need
    • Scientific Resources
    • Scientific Advisory Board
    • Pipeline
    • Grants
  • Investors & Media
    • Overview
    • Newsroom
    • Events
    • Financial Information
    • Stock Information & Analyst Coverage
    • FAQs

Newsroom

Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9
May 04, 2023
PDF Version
Esperion to Participate in JMP Securities Life Sciences Conference
May 01, 2023
PDF Version
Esperion to Participate in Bank of America Securities 2023 Health Care Conference
Apr 27, 2023
PDF Version
Esperion to Report First Quarter 2023 Financial Results May 9, 2023
Apr 25, 2023
PDF Version
Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC
Apr 19, 2023
PDF Version
  • First page «
  • Previous page ‹
  • …
  • Page 25
  • Page 26
  • Current page 27
  • Page 28
  • Page 29
  • …
  • Next page ›
  • Last page »

Media Information

To speak with a member of our PR team, or to schedule an interview, please contact Esperion Corporate Communications by phone at +1 734-887-3903, or by email at corporateteam@esperion.com.


 
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

 
Corporate Inquiries & Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

 

Email Alerts

  • OUR COMPANY
  • About Us
  • Leadership Team
  • Board of Directors
  • Ethics and Compliance
  • Corporate Governance & Committee Composition
  • PRODUCTS
  • SCIENCE
  • Unmet Need
  • Scientific Resources
  • Scientific Advisory Board
  • Pipeline
  • Grants
  • CAREERS
  • Partnerships & Business Development
  • INVESTORS & MEDIA
  • Overview
  • Newsroom
  • Events
  • Financial Information
  • Stock Information & Analyst Coverage
  • FAQs
  • Contact Us
Great place to work certified | JUN 2024 - JUN 2025 | USA

All trademarks and trade names are the property of their respective owners.

© 2026 Esperion Therapeutics, Inc. All rights reserved.

  • Privacy Policy
  • Terms of Use
  • Accessibility Statement
  • Social Media Community Guidelines
  • facebook
  • instagram
  • linkedin
  • twitter
  • rss
Search Investors